Introduction:
A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March 2013 issue of Nature by Prof Dimmler, Boon, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for Myocardial Infarction: Ampelopsin (AMP), a flavnol mainly found in Ampelopsis grossedentata (commonly known as Mayeam), improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10)
Significance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug with known mechanism of action.
Research findings:
I have shown recently that Ampelopsin (AMP), by decreasing the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase), it may promote (1) resistance to bone, immune, and motor dysfunction; (2) insulin sensitivity; and (3) longevity.
This study suggests a natural product-based cardiac regeneration therapy. Ampelopsin, by increasing the expression of its target gene, it may increase the expression of PNUTS/PPP1R10. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration.
Ampelopsin (AMP) , isolated from Ampelopsis grossedentata (commonly known as Mayeam), promotes myocardial survival and prevents myocardial infarction via up-regulation of PNUTS/PPP1R10
AMP is found abundantly in”Mayeam.” The leaves and stems of Mayeam are used to make a herbal tea generally known as Tujia God/heaven tea. The average life span of those who consume this tea regularly is 89 years.
Therapeutic opportunity:
Given that Natural product “Ampelopsin” has a longevity-promoting effect, as discussed above, it may be a drug of choice for cardiac regeneration therapy.
Thus, by treating myocardial patients with Ampelopsin or advising cardiac patients to drink Mayeam/herbal/ Tujia God/heaven tea enriched with Ampelopsin regularly, one may prevent ageing-associated (or, stress-associated) decline in cardiac function.
Together, this study suggests that pharmacological formulations encompassing “Ampelopsin or its analogs may be used to improve cardiac function after myocardial infarction.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web:http://genomediscovery.org or http://newbioideas.com
To cite: Boominathan, Natural product therapy for Myocardial Infarction: Ampelopsin (AMP), a flavnol mainly found in Ampelopsis grossedentata (commonly known as Mayeam), improves myocardial function after myocardial infarction via up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 28/October/2016, 10.29 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Undisclosed information: How Ampelopsin (AMP) increases the expression of PNUTS/PPP1R10 and improves myocardial function
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $300#
Results guaranteed if not refunded
# Research cooperation